Gonadal Pharmacology · Module 4 of 5

Ovulation Induction and ART Pharmacology

Clomiphene, letrozole, gonadotropins, ART protocols, and OHSS

Clomiphene and letrozole both raise FSH by different mechanisms — clomiphene blocks hypothalamic estrogen receptors throughout the body creating a perceived estrogen deficit, while letrozole inhibits aromatase to transiently lower estradiol; because letrozole leaves estrogen receptors intact, the developing follicle's own estradiol can produce a normal endometrium and cervical mucus, explaining letrozole's superior live birth rates and lower multiple gestation risk in PCOS ovulation induction.
Gonadotropin selection must respect the two-cell model — in WHO Group I anovulation (hypogonadotropic hypogonadism), both FSH and LH are absent; FSH alone cannot stimulate estrogen production because there is no LH to drive theca cell androgen synthesis, leaving granulosa aromatase without substrate; these patients require human menopausal gonadotropin or combined recombinant FSH + LH, not FSH alone.
The GnRH antagonist protocol has largely replaced the long agonist protocol in IVF because it enables a GnRH agonist ovulation trigger — replacing hCG with a brief endogenous LH surge that does not sustain LH receptor stimulation on the multiple corpora lutea, eliminating the primary driver of OHSS; this single intervention reduces severe OHSS from approximately 1–2% to near zero in high-risk patients.
OHSS is a VEGF-mediated capillary leak syndrome: hCG (endogenous or exogenous) triggers sustained LH receptor stimulation on hyperstimulated ovaries containing multiple corpora lutea, which produce massive VEGF; VEGF increases endothelial permeability, driving protein-rich fluid from the intravascular compartment into the peritoneal and pleural spaces, producing ascites, hemoconcentration, and high VTE risk.
Freeze-all prevents late OHSS — the early OHSS from the hCG trigger resolves on its own, but late OHSS driven by embryonic hCG production from an implanting pregnancy is more severe and prolonged; freezing all embryos and deferring transfer to a subsequent natural or hormone-prepared cycle eliminates this embryonic hCG exposure entirely.

Abbreviations: FSH = follicle-stimulating hormone · LH = luteinizing hormone · PCOS = polycystic ovary syndrome · GnRH = gonadotropin-releasing hormone · hCG = human chorionic gonadotropin · VEGF = vascular endothelial growth factor · OHSS = ovarian hyperstimulation syndrome · ART = assisted reproductive technology · IVF = in vitro fertilization · AMH = anti-Müllerian hormone · LMWH = low-molecular-weight heparin · VTE = venous thromboembolism · WHO = World Health Organization

Oral Ovulation Induction — Clomiphene vs. Letrozole

Feature	Clomiphene Citrate	Letrozole	Clinical Implication
Mechanism	Blocks hypothalamic ER → perceived estrogen deficiency → FSH rise	Inhibits aromatase (CYP19A1) → transient estrogen drop → FSH rise	Same end result (FSH rise), different routes — letrozole preserves ER function
ER status	Blocked throughout body — long half-life occupies ER for weeks	Intact — free to respond normally to follicular estradiol	Letrozole allows normal endometrial and cervical response
Endometrium	Thin, poorly proliferating — anti-estrogenic effect impairs implantation	Normal proliferation once follicle produces estradiol	Better implantation environment with letrozole
Cervical mucus	Viscous, impermeable — ER blockade prevents estrogen thinning	Normal permeability	Better sperm penetration with letrozole
Multiple gestation	Higher (∼8–13%) — no intact feedback to limit recruitment	Lower (∼3–7%) — intact feedback limits excess follicle recruitment	Intact HPO axis with letrozole provides self-limiting response
Preferred use	Second-line in some non-PCOS anovulatory infertility	First-line for PCOS ovulation induction (NEJM 2014 — superior live birth rates)	Letrozole is standard of care for PCOS per ASRM/ESHRE guidelines

Gonadotropin Preparations — WHO Classification

WHO Group I — Hypogonadotropic Hypogonadism

Requires FSH + LH

Both FSH and LH absent or minimal — pituitary or hypothalamic failure
FSH alone fails: no LH → no theca androgen production → granulosa aromatase has no substrate → no estradiol
Treatment: human menopausal gonadotropin (hMG — FSH + LH activity) OR recombinant FSH + recombinant LH
Two-cell model principle: LH drives theca androgens; FSH converts them to estradiol via aromatase

WHO Group II — Normal Gonadotropins (PCOS, Most Cases)

FSH Alone Sufficient

Endogenous LH present — theca androgen production intact
Recombinant FSH (follitropin alfa or beta) or urinary FSH appropriate
Recombinant preparations: consistent potency batch-to-batch, subcutaneous pen device
Urinary preparations: lower cost, generally equivalent live birth rates in meta-analyses
PCOS caution: high AMH and LH sensitivity → start low, titrate slowly to avoid OHSS

ART Stimulation Protocols

Older — Longer Protocol

Long GnRH Agonist Protocol

GnRH agonist started mid-luteal phase → full pituitary downregulation (10–14 days)
Then begin FSH stimulation; continue agonist throughout to prevent premature LH surge
Total duration: ~4–6 weeks from agonist start
Cannot use GnRH agonist trigger — pituitary already downregulated; must use hCG
Higher OHSS risk in high responders because hCG trigger is required

Preferred — Shorter Protocol

GnRH Antagonist Protocol

Start FSH stimulation cycle day 1–2; add antagonist when leading follicle reaches ~14 mm (day 5–6)
Immediate receptor blockade — no flare; pituitary remains responsive
Total duration: ~10–14 days
Enables GnRH agonist trigger → brief endogenous LH surge → near-zero severe OHSS
Preferred for PCOS, high AMH, egg freezing, and most patients today

OHSS — Pathophysiology and Prevention

Pathophysiology

VEGF → Capillary Leak → Third-Space Shift

hCG → sustained LH receptor stimulation on multiple corpora lutea simultaneously
Multiple corpora lutea → massive VEGF production from luteinized granulosa cells
VEGF → endothelial permeability ↑ → protein-rich fluid extravasates → ascites, pleural effusion
Intravascular hypovolemia + hemoconcentration → VTE risk (leading preventable cause of death)
Early OHSS: triggered by exogenous hCG (days 3–9 post-trigger)
Late OHSS: triggered by embryonic hCG from implantation (weeks 4–6) — more severe, more prolonged

Prevention and Management

Hierarchy of Interventions

Best prevention: GnRH agonist trigger (antagonist protocol only) — brief LH surge, rapid luteolysis, near-zero severe OHSS
Freeze-all embryos: prevents late OHSS by eliminating embryonic hCG exposure this cycle
Cabergoline (dopamine agonist): adjunct when hCG trigger required — modulates VEGF receptor phosphorylation → reduces vascular permeability
Start FSH at low dose in PCOS/high-AMH patients — limit follicle cohort size
Severe OHSS management: IV crystalloid, ultrasound-guided paracentesis, LMWH anticoagulation

hCG Drives OHSS — Eliminate It to Eliminate OHSS

Human chorionic gonadotropin — whether from an exogenous trigger injection or from an implanting embryo — is the proximal cause of OHSS. It provides sustained LH receptor stimulation to the hyperstimulated ovaries, driving massive VEGF production from multiple corpora lutea. VEGF then increases endothelial permeability, producing the third-space fluid shift that defines the syndrome.

The GnRH agonist trigger replaces exogenous hCG with a brief, self-limited endogenous LH surge that is insufficient to sustain LH receptor stimulation — eliminating early OHSS. The freeze-all strategy eliminates embryonic hCG — eliminating late OHSS. Together they reduce severe OHSS incidence to near zero in the highest-risk patients.

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 40: Estrogens, Progestins, and the Female Reproductive Tract	McGraw-Hill; 2021
Brunton L, Knollmann B, Hilal-Dandan R, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 44: Estrogens and Progestins	McGraw-Hill; 2023
Adashi EY.	Clomiphene citrate: mechanism(s) and site(s) of action — a hypothesis revisited	Fertil Steril. 1984;42(3):331–344
Legro RS, Brzyski RG, Diamond MP, et al; NICHD Reproductive Medicine Network.	Letrozole versus clomiphene for infertility in the polycystic ovary syndrome	N Engl J Med. 2014;371(2):119–129
Mitwally MF, Casper RF.	Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate	Fertil Steril. 2001;75(2):305–309
Balen AH, Platteau P, Andersen AN, et al.	The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with WHO Group II anovulatory infertility	BJOG. 2006;113(10):1195–1202
Devroey P, Boostanfar R, Koper NP, et al; ENGAGE Investigators.	A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first 7 days of ovarian stimulation using a GnRH antagonist protocol	Hum Reprod. 2009;24(12):3063–3072
Miyamoto K, Hasegawa Y, Igarashi M, et al.	Identification of the second gonadotropin-releasing hormone in chicken hypothalamus	Proc Natl Acad Sci USA. 1984;81(12):3874–3878
van der Linden M, Buckingham K, Farquhar C, et al.	Luteal phase support for assisted reproduction cycles	Cochrane Database Syst Rev. 2015;7:CD009154
Humaidan P, Quartarolo J, Papanikolaou EG.	Preventing ovarian hyperstimulation syndrome: guidance for the clinician	Fertil Steril. 2010;94(2):389–400
Fauser BC, Diedrich K, Devroey P; Evian Annual Reproduction Workshop Group 2007.	Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation	Hum Reprod Update. 2008;14(1):1–14
Delvigne A, Rozenberg S.	Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome	Int J Fertil Womens Med. 2002;47(5):211–226
Royal College of Obstetricians and Gynaecologists.	Ovarian Hyperstimulation Syndrome: Green-top Guideline No. 5	RCOG Press; 2016
Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al.	Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction	J Clin Endocrinol Metab. 2007;92(8):2931–2937